Proteomics: The Omics Series — Part I

Executive Summary

Proteomics is the large-scale study of proteins: their structure, function, quantity, and interactions across biological systems. It is one of the fastest-growing segments in the life sciences tools market, valued at approximately $28-36 billion globally in 2024 depending on scope, and projected to reach $58-145 billion by 2030-2034 across various analyst estimates, with CAGRs consistently in the 12-15% range.

The market is driven by three durable forces: the shift toward precision medicine, the acceleration of AI-enabled drug discovery, and the growing recognition that proteins, not genes, are where biology actually executes. Genomics told us the blueprint. Proteomics reads the building.

For investors and business owners in the life sciences sector, proteomics presents a compelling opportunity profile: high-margin consumables businesses, recurring revenue, significant IP protection, an active strategic acquirer universe, and a fragmented middle market that remains largely unconsolidated. The recent wave of multi-billion dollar acquisitions by Thermo Fisher, Danaher, and Bruker signals where the large-cap players are placing their bets. The question for smaller operators is how to position to participate in the next wave.

This report covers the full landscape: what proteomics is and why it matters, how the market segments, who the key players are, how the supply chain works, what transactions have defined the space, what the hot scientific and commercial topics are in 2025, the regulatory environment, and what makes a proteomics company genuinely defensible in a competitive market.

Section 1: What Is Proteomics?

The Protein as the Unit of Function

Every living cell contains thousands of proteins. These proteins carry out virtually every biological function: they catalyze reactions, transmit signals, build structures, defend against pathogens, and regulate gene expression. The genome tells a cell what proteins it could make. The proteome tells us what proteins it is actually making, in what quantities, in what state, and in what context, at any given moment.

Proteomics is the discipline that studies the proteome systematically. Where genomics is largely fixed (your DNA sequence is the same in every cell of your body and changes little over your lifetime), the proteome is dynamic. It changes by cell type, tissue, disease state, drug exposure, time of day, and environmental condition. This dynamism is both what makes proteomics scientifically powerful and what makes it technically challenging.

Why Proteomics Matters More Than Genomics for Drug Discovery

The central argument for proteomics over genomics in therapeutic development is direct relevance. Almost all drugs work by interacting with proteins, not genes. A drug that inhibits an enzyme, blocks a receptor, or disrupts a protein-protein interaction is operating at the protein level. Understanding the proteome at high resolution means understanding the drug's actual target, its off-target effects, its mechanism of resistance, and its relationship to disease progression.

Genomics has been enormously valuable for identifying disease-associated variants and predicting risk. But the gap between a genetic variant and a clinical outcome is filled with protein biology. Many genetic variants have no functional consequence because their protein-level effects are buffered by other cellular processes. Proteomics closes that gap.

The Nobel Prize in Chemistry awarded to AlphaFold's developers in 2024 was a signal of how central protein science has become to the future of medicine. The ability to predict protein structures computationally has accelerated what proteomics can do experimentally, and the two fields are converging rapidly.

Proteomics vs. Other Omics

To place proteomics in context within the broader omics landscape:

Genomics studies the complete set of DNA in an organism. It is largely static and well-established commercially, dominated by next-generation sequencing platforms.

Transcriptomics studies RNA, the intermediate step between DNA and protein. It provides a snapshot of which genes are being expressed but not what those gene products are actually doing.

Proteomics studies proteins directly. It captures post-translational modifications (phosphorylation, glycosylation, ubiquitination) that genomics and transcriptomics cannot see and that are often the functional mechanism of disease.

Metabolomics studies small molecules and metabolites, the downstream products of protein activity.

Multi-omics refers to the integration of two or more of these data types. The convergence of genomics, transcriptomics, and proteomics into integrated datasets is one of the hottest areas in life sciences research and a growing driver of proteomics demand.

Section 2: Market Size and Segments

Overall Market

The global proteomics market was valued at approximately $28-36 billion in 2024, depending on the scope of measurement. The most commonly cited projections show the market reaching $58-100+ billion by 2030-2032, with CAGRs consistently in the 12-15% range. North America accounts for approximately 44-48% of global revenue, with the United States alone representing roughly $12-17 billion of the 2024 total. Asia-Pacific is the fastest-growing region, expanding at a 14-16% CAGR driven by rising biopharma investment and proteomics adoption in China, Japan, and India.

By Product and Service

Reagents and consumables dominate the market with approximately 70-73% of revenue in 2024. This segment includes antibodies, buffers, enzymes, enrichment kits, labeling reagents, chromatography consumables, and all other disposable products used in proteomics workflows. The consumables-heavy nature of proteomics is a defining financial characteristic of the industry and the reason gross margins for specialized suppliers regularly exceed 60-70%.

Instruments represent a meaningful but smaller share, including mass spectrometers, chromatography systems, protein microarray platforms, and liquid handling automation. Instrument revenue benefits from premium pricing on next-generation platforms but is inherently more cyclical than consumables.

Software and bioinformatics is the fastest-growing subsegment by CAGR, expanding at approximately 13-14% annually. As proteomics datasets grow in complexity and scale, the ability to process, annotate, and extract biological meaning from the data has become as valuable as the ability to generate it. Cloud-native platforms, AI-assisted annotation, and subscription licensing models are reshaping how bioinformatics revenue is captured.

Services (CRO-style proteomics) are also growing rapidly as academic and commercial laboratories outsource mass spectrometry analysis, protein identification, and bioinformatics to specialized providers. The CRO segment is expanding at nearly 13% CAGR through 2030.

By Technology

Mass spectrometry is the dominant analytical technology, capturing approximately 30-32% of market revenue in 2024. Mass spectrometers identify and quantify proteins by measuring the mass-to-charge ratio of ionized peptide fragments. Modern Orbitrap-based platforms from Thermo Fisher can identify thousands of proteins in a single run. The technology is advancing rapidly: Thermo Fisher's Stellar Mass Spectrometer, introduced in 2024-2025, delivers sub-2-hour deep proteome coverage that previously required overnight runs.

Chromatography (primarily liquid chromatography, or LC) is almost always paired with mass spectrometry in what is known as LC-MS/MS workflows. Chromatography separates complex protein mixtures before they enter the spectrometer, enabling much deeper coverage of low-abundance proteins that would otherwise be masked by highly abundant species like albumin.

Affinity-based platforms are a distinct and fast-growing technology category. Rather than separating proteins by mass, affinity platforms use antibodies or aptamers to selectively capture specific proteins from complex biological samples like blood plasma. Olink's Proximity Extension Assay (PEA) technology and SomaLogic's SomaScan aptamer platform are the two dominant commercial examples. These platforms sacrifice the breadth of untargeted mass spectrometry for much higher throughput, ease of use, and clinical applicability.

Next-generation sequencing (NGS)-adjacent methods are the fastest-growing technology segment. DNA-encoded antibody libraries and ribosome-display systems allow proteomics readouts on sequencing platforms, enabling extremely high-multiplex protein quantification at scale.

Spatial proteomics is an emerging but rapidly growing technology category that earned recognition as Nature Methods' Method of the Year for 2024. Spatial proteomics maps protein expression directly within intact tissue sections, preserving the architectural context that bulk proteomics destroys. Methods include multiplexed immunofluorescence, imaging mass cytometry, MALDI imaging, and laser capture microdissection combined with downstream mass spectrometry.

By Application

Drug discovery and development is the largest application segment, accounting for approximately 49-53% of market revenue in 2024. Pharmaceutical and biotechnology companies use proteomics to identify novel drug targets, understand mechanisms of action, characterize drug-protein interactions, and detect off-target effects. Mass spectrometry-based chemoproteomics approaches are now standard in major pharma pipelines.

Biomarker discovery is a distinct but related application, focused on identifying protein signatures associated with disease states, treatment response, or disease progression. Plasma-based biomarker discovery has accelerated dramatically with the maturation of high-multiplex affinity platforms that can measure thousands of proteins from a blood draw.

Clinical diagnostics is the fastest-growing application segment by CAGR (approximately 14-15% through 2030). The translation of research proteomics into clinical diagnostic tests represents the largest near-term commercial opportunity in the space. The pathway from Research Use Only (RUO) to In Vitro Diagnostic (IVD) approval is complex but increasingly well-navigated by companies with clinical proteomics assets.

Personalized medicine is advancing at a 14% CAGR, driven by the integration of protein biomarker data into treatment selection algorithms in oncology, neurology, and cardiovascular disease.

By End User

Pharmaceutical and biotechnology companies are the dominant end users, accounting for approximately 73-74% of market revenue in 2024. Academic and research institutions are important volume customers but lower-margin ones. Contract Research Organizations are the fastest-growing end-user segment as outsourcing of proteomics workflows accelerates.

Section 3: Technology Landscape

Mass Spectrometry: The Core Platform

Mass spectrometry-based proteomics has been the workhorse of the field for two decades and remains the most comprehensive tool for protein identification and quantification. Modern instruments can identify and quantify tens of thousands of proteins in a single biological sample.

The workflow begins with sample preparation: cells or tissues are lysed, proteins are extracted and digested into peptides using enzymes like trypsin, and the resulting peptide mixture is cleaned and loaded onto a liquid chromatography column. The LC separates the peptides by hydrophobicity before they enter the mass spectrometer, where they are ionized, fragmented, and detected. Bioinformatics tools then match the mass spectra against protein sequence databases to identify and quantify the proteins present.

Key developments in mass spectrometry over the past three years include significant advances in scan speed, resolution, and sensitivity. Time-of-flight/Orbitrap hybrid instruments deliver sub-ppm mass accuracy at speeds that support population-scale cohort studies of hundreds of thousands of samples. Data-independent acquisition (DIA) methods have improved reproducibility dramatically compared to older data-dependent approaches.

Affinity-Based Platforms: The Clinical Translation Layer

While mass spectrometry provides comprehensive coverage, it requires significant sample preparation, expensive instrumentation, and expert operators. Affinity-based platforms trade some breadth for dramatically improved throughput, ease of use, and clinical applicability.

Olink Proteomics (acquired by Thermo Fisher for $3.1 billion in 2024) developed the Proximity Extension Assay (PEA) technology, which uses pairs of antibodies linked to DNA oligonucleotides. When both antibodies bind the same protein target, the DNA strands extend and are amplified, generating a highly specific readout. The Explore HT platform can measure approximately 5,400 proteins from a single blood sample. The UK Biobank selected Olink's platform for the largest human proteome study ever conducted, profiling 5,400 proteins across 600,000 samples.

SomaLogic (now part of Standard BioTools after a 2023 merger) developed the SomaScan platform using aptamers, which are short single-stranded DNA or RNA molecules that fold into specific three-dimensional shapes to bind target proteins with high specificity. SomaScan can measure approximately 7,000 proteins from a small plasma sample.

Alamar Biosciences raised $128 million in March 2024 to commercialize an ultra-sensitive proximity ligation assay platform designed for early disease detection from very small sample volumes.

Spatial Proteomics: The Emerging Frontier

Spatial proteomics adds a dimension that bulk proteomics has always lacked: location. In a tumor, for example, proteins at the invasive edge behave differently from proteins in the core, and proteins on immune cells infiltrating the tumor behave differently from proteins on the malignant cells themselves. Bulk proteomics averages all of these together and loses the biological signal.

Spatial proteomics platforms, including Akoya Biosciences' Phenocycler Fusion (multiplexed immunofluorescence), Lunaphore's COMET, and mass spectrometry imaging approaches using MALDI, allow researchers to map protein expression at single-cell resolution within intact tissue sections. The field was named Nature Methods' Method of the Year for 2024, signaling its transition from specialized technique to mainstream research tool.

Bioinformatics and AI Integration

The bottleneck in proteomics has shifted. The instruments can now generate more data than most laboratories can analyze. Cloud-native bioinformatics platforms, AI-assisted protein annotation, and machine learning models trained on large proteomics datasets are rapidly becoming as commercially important as the wet lab tools that generate the data. This is driving the rapid growth of the software and services segment and attracting significant investment from both strategic and financial buyers.

Section 4: Key Players

Established Leaders

Thermo Fisher Scientific is the dominant force in proteomics instrumentation and reagents globally. Its Orbitrap mass spectrometry platform is the industry standard for deep proteome coverage. The 2024 acquisition of Olink for $3.1 billion added a leading affinity-based proteomics platform and created what is arguably the most complete sample-to-insight proteomics workflow available commercially. Revenue from the Life Sciences Solutions segment, which includes proteomics tools, exceeds $10 billion annually.

Danaher Corporation operates in proteomics primarily through its Cytiva and Beckman Coulter Life Sciences subsidiaries, covering protein separation, purification, and workflow automation. The 2023 acquisition of Abcam for approximately $5.7 billion added a world-class antibody and protein reagent portfolio that directly serves proteomics workflows.

Bruker Corporation has emerged as one of the most aggressive strategic actors in proteomics over the past three years. Its timsTOF series of mass spectrometers (particularly the timsTOF Ultra and the timsTOF SCP for single-cell proteomics) has been adopted rapidly in research labs globally. Bruker's strategic partnership with Biognosys, a leading CRO for proteomics services, and its acquisition of NanoString's spatial multi-omics capabilities, position it as a comprehensive proteomics platform company.

Agilent Technologies is a significant player in LC systems and columns, mass spectrometry instruments, and bioinformatics software for proteomics. Its InfinityLab LC Series, updated in October 2024, is widely used in proteomics workflows.

Bio-Rad Laboratories is a major supplier of electrophoresis systems, protein assays, antibodies, and western blotting reagents that are foundational to proteomics sample preparation and validation workflows.

Merck KGaA (operating as MilliporeSigma in North America) is a broad-based life sciences tools supplier with significant positions in proteomics reagents, specialty chemicals, and sample preparation products.

Waters Corporation is a leading provider of LC systems and mass spectrometry instruments. Its January 2025 merger agreement with BD (Becton Dickinson) in a $17.5 billion deal creates a combined entity spanning chemistry, mass spectrometry, and immunoassay capabilities with significant proteomics relevance.

Emerging and Growth-Stage Players

Biognosys (Basel/Boston) is one of the leading CROs for mass spectrometry-based proteomics services, with particular expertise in data-independent acquisition (DIA-MS). Bruker's strategic partnership and CHF 75 million investment positions Biognosys as the leading proteomics CRO globally.

Alamar Biosciences raised $128 million in March 2024 for its NULISA (Nucleic acid Linked Immuno-Sandwich Assay) platform, designed for ultra-sensitive protein detection from ultra-low sample volumes.

Standard BioTools (formerly Fluidigm, post-merger with SomaLogic) operates the SomaScan platform and a portfolio of mass cytometry (CyTOF) instruments for high-dimensional protein analysis at the single-cell level.

Quantum-Si is commercializing next-generation protein sequencing using semiconductor chip technology. Its Platinum Pro benchtop sequencer detects single amino acids through binding kinetics, enabling detection of protein variants that conventional mass spectrometry may miss.

Seer is developing a nanoparticle-based proteomics workflow (Proteograph) designed to dramatically simplify and accelerate deep plasma proteomics by enabling unbiased, high-throughput protein enrichment.

Syncell (founded 2020, Series A of $15 million in December 2024) has developed the Microscoop platform for microscopy-guided spatial protein purification.

Quanterix integrates Akoya Biosciences' spatial-omics capabilities to deliver both blood-based and tissue-context protein biomarker detection, with a particular focus on neurology and Alzheimer's disease biomarkers.

Section 5: Supply Chain

Upstream: Raw Materials and Components

The proteomics supply chain begins with raw materials: chemical precursors for reagent synthesis, biological source materials for antibody production (including animal-derived sera and cell lines), and specialty components for instrument manufacturing.

Raw material concentration is a meaningful risk for the industry. Many specialized reagents depend on biological source materials that are difficult to substitute. Trypsin, the most widely used enzyme for protein digestion in mass spectrometry workflows, is produced by a small number of specialized suppliers. Any supply disruption to high-purity, sequence-grade trypsin would affect virtually every proteomics laboratory in the world.

Geographic concentration in Asia, particularly China, for certain raw material inputs creates supply chain risk that the COVID-19 pandemic made viscerally real. The current U.S. tariff environment is adding cost pressure to imported reagent components and instruments.

Midstream: Instrument and Reagent Manufacturers

The commercial core of the proteomics supply chain is the instrument and reagent manufacturing layer. This is where the highest margins, the most significant IP concentration, and the most active M&A occurs.

The major instrument manufacturers (Thermo Fisher, Bruker, Agilent, Waters, Sciex) operate integrated supply chains that combine precision electronics, specialized optics, and proprietary software into platforms sold to research and clinical laboratories worldwide.

Reagent manufacturers range from the large diversified suppliers to hundreds of specialized niche suppliers producing proprietary antibodies, enrichment kits, labeling reagents, or specialty enzymes. The smaller specialized reagent companies are the primary targets of consolidation activity.

Midstream: Distribution

The distribution layer is dominated by the same broadline distributors that serve the broader life sciences industry: Thermo Fisher Scientific (Fisher Scientific), Avantor (VWR), Sigma-Aldrich (part of Merck KGaA), and Henry Schein Scientific.

The OEM and private label segment is a meaningful channel for proteomics reagents. Many CROs and diagnostics companies source reagents from specialized manufacturers and rebrand them under their own labels.

Downstream: End Users and Services

End users of proteomics tools fall into four categories. Pharmaceutical and biotechnology companies (approximately 73% of revenue) are the primary commercial end market. Academic and research institutions are volume-intensive customers but price-sensitive. CROs provide proteomics services to pharma clients on an outsourced basis, with growing market share. Clinical diagnostic laboratories represent the emerging clinical translation market.

The Bioinformatics Layer

Proteomics experiments generate extraordinarily complex datasets. A single DIA-MS run might produce gigabytes of raw data that must be processed through multiple software steps before biological conclusions can be drawn.

The key software platforms in proteomics bioinformatics include Spectronaut (Biognosys), DIA-NN (open source), MaxQuant (Max Planck Institute, open source), Proteome Discoverer (Thermo Fisher), and a growing ecosystem of cloud-native and AI-augmented analysis tools.

Section 6: M&A and Investment Activity

The Strategic Acquisition Wave

The proteomics space has been defined by large-cap strategic acquisitions over the past three years, with deals totaling tens of billions of dollars. The common thread across all of them is the same: large instrument companies buying platform-level proteomics capabilities to create vertically integrated sample-to-insight workflows.

Thermo Fisher / Olink ($3.1 billion, completed July 2024). The defining deal of the current cycle. Thermo Fisher acquired Olink, whose Proximity Extension Assay technology measures thousands of proteins from a blood sample with exceptional sensitivity and clinical applicability. The deal was valued at 8-10x revenue.

Danaher / Abcam ($5.7 billion, completed August 2023). Danaher's acquisition of Abcam is the largest pure-play proteomics tools acquisition in history. Abcam had built one of the world's largest catalogs of validated research antibodies and protein assays, serving virtually every proteomics workflow at the reagent level.

Bruker / NanoString spatial omics capabilities. Bruker acquired NanoString's spatial transcriptomics and proteomics capabilities as part of NanoString's bankruptcy process.

Bruker / ELITech (EUR 870 million, 2024). The ELITech acquisition reinforces Bruker's diagnostic kit offerings.

SomaLogic / Standard BioTools merger (2023). The all-stock combination created a company with both the SomaScan affinity proteomics platform and CyTOF mass cytometry capabilities.

Quanterix / Akoya Biosciences. Quanterix integrated Akoya's spatial-omics portfolio to deliver both blood-based and tissue-context protein biomarker detection.

Venture and Growth Investment

At the growth-stage level, several significant rounds signal where the next wave of strategic acquisitions is likely to come from: Alamar Biosciences raised $128 million in March 2024. Syncell closed a $15 million Series A in December 2024. Pluto Bio secured $3.6 million in May 2025 for AI-driven multi-omics analytics. Proteomics International Laboratories secured $4.5 million in April 2025 for its Promarker diagnostic platform.

The pattern in venture investment mirrors the M&A pattern: money is flowing toward clinical translation, AI-enabled data analysis, and spatial/single-cell platforms.

Section 7: Hot Topics in 2025

Spatial Proteomics: Method of the Year

Nature Methods named spatial proteomics its Method of the Year for 2024, the strongest possible signal from the academic community that a technique has crossed from specialized tool to mainstream platform. Commercially, the spatial proteomics market is projected to grow from approximately $88 million in 2024 to $358 million by 2034 at a 15% CAGR.

Population-Scale Plasma Proteomics

The UK Biobank's decision to profile 5,400 proteins across 600,000 samples using Olink's platform is the most prominent example. Regeneron's collaboration with Ultima Genomics covers 200,000 samples from the Geisinger Health Study.

These population-scale datasets are generating protein-trait association studies (analogous to GWAS but at the protein level) that are identifying new drug targets and biomarkers at a pace previously impossible.

Single-Cell Proteomics

Single-cell proteomics is attempting to do for proteins what single-cell RNA sequencing did for gene expression, but it is technically harder because proteins cannot be amplified the way DNA and RNA can. Recent advances in mass spectrometry sensitivity (particularly Bruker's timsTOF SCP) are making single-cell proteomics increasingly practical.

AI and Machine Learning Integration

The integration of AI into proteomics is happening at multiple levels simultaneously. The convergence of AlphaFold-based protein structure prediction with experimental proteomics data is accelerating drug target identification. Companies like AI Proteins (Bristol Myers Squibb, $400 million deal) and Orionis Biosciences (Genentech, $105 million upfront) are building drug discovery pipelines at the intersection of computational protein biology and experimental proteomics.

GLP-1 Drugs and Proteomics Research

Proteomics is playing a central role in understanding the multi-system effects of GLP-1 receptor agonists like semaglutide. Novo Nordisk is compiling proteomics data from the SELECT trial, covering 17,000 overweight participants. The question of whether GLP-1 drugs have protein-level effects on addiction, inflammation, and neurodegeneration is being answered through plasma proteomics studies.

Clinical Translation: RUO to IVD

The pathway from Research Use Only proteomics tools to clinically validated IVD tests is the most commercially significant near-term opportunity in the space. Protein biomarkers for Alzheimer's disease (particularly plasma phospho-tau and GFAP), cancer (liquid biopsy applications), cardiovascular disease, and infectious disease are advancing through clinical validation.

Section 8: Regulatory Environment

The IVD Pathway for Protein Biomarkers

Proteomics-based diagnostics fall under the In Vitro Diagnostic (IVD) regulatory framework in both the United States (FDA) and Europe (CE-IVD under the European IVD Regulation, or IVDR). The regulatory distinction between Research Use Only (RUO) and IVD status is commercially critical because IVD-cleared products can be used for clinical decision-making.

In the United States, the FDA's recent regulatory activity around Laboratory-Developed Tests (LDTs) has created meaningful uncertainty for proteomics-based clinical assays. The FDA's April 2024 final rule reclassifying LDTs as medical devices was overturned by a federal court in March 2025, but the regulatory direction of travel is toward tighter oversight.

Quality Standards

ISO 13485 certification is the baseline quality management standard for medical device and IVD companies. For clinical-grade mass spectrometry, the Clinical Laboratory Improvement Amendments (CLIA) framework governs laboratory operations, and College of American Pathologists (CAP) accreditation is the standard for clinical proteomics service labs.

International Regulatory Dynamics

Europe's IVDR, which took full effect in 2022, imposes substantially more rigorous requirements on IVD manufacturers than the previous IVD Directive. This regulatory complexity creates both a challenge and an opportunity for companies already invested in quality systems.

Section 9: What Makes a Proteomics Company Defensible?

Intellectual Property

The most durable competitive moats in proteomics are built on intellectual property. This includes patents on novel assay chemistries, antibody sequences and production processes, platform-specific data acquisition methods, and software algorithms for data analysis. Olink's PEA technology and SomaLogic's aptamer panel are examples of IP-anchored platforms that justified multi-billion dollar acquisition premiums.

Validation Data

In proteomics, validated data is a genuine competitive asset. Once a reagent, assay, or workflow has been validated in a peer-reviewed publication or incorporated into a multi-site clinical study, that validation creates switching costs for every laboratory that has built its processes around the validated tool.

Strategic acquirers specifically value proteomics assets that have appeared in high-profile publications or been used in large population studies.

Clinical Partnerships and Pharma Relationships

Long-term collaborative agreements with major pharmaceutical companies represent some of the most defensible revenue in the proteomics market. When a pharma company licenses a specific proteomics platform for use across its clinical pipeline, the switching cost is enormous.

Companies with two or more anchor pharma collaborations at the platform level have demonstrated both technical credibility and commercial defensibility that pure research-tool companies cannot match.

Platform vs. Catalog

There is a meaningful valuation distinction between proteomics companies that operate as platforms (a system of instruments, reagents, and software that customers are trained to use as an integrated workflow) and those that operate as reagent catalogs. Platform companies command higher multiples because the switching cost is much higher.

Section 10: M&A Implications for Private Proteomics Companies

Who Is Buying and Why

The strategic acquirer universe for proteomics companies falls into three categories. The large instrument and life sciences tools companies (Thermo Fisher, Danaher, Bruker, Agilent, Waters) are buying capabilities that extend their workflow coverage or add clinical translation potential. They are paying 4-10x revenue for assets with strong IP, clinical readiness, and recurring revenue.

Mid-size strategic acquirers are buying for geographic expansion, specific technical capabilities, or channel access. These deals tend to be smaller but can still achieve meaningful multiples.

Private equity is increasingly active in the proteomics tools space, primarily through the same roll-up logic that has driven consolidation in other life sciences tool categories.

Valuation Framework

Private proteomics companies are valued on a combination of revenue multiples and EBITDA multiples. Current market ranges:

Companies under $10 million in revenue with research-focused product lines typically trade at 2-4x revenue.

Companies with $10-100 million in revenue, established customer bases, and proven recurring revenue models command 4-7x revenue at midpoint, with premiums for clinical readiness, strong IP, and pharma partnerships.

Platform-quality assets with clinical validation, large-cohort study penetration, or unique technology that creates workflow lock-in have achieved 8-10x revenue in strategic transactions (Olink being the clearest benchmark).

EBITDA multiples for profitable proteomics tools businesses typically range from 12-20x.

What Buyers Are Specifically Looking For

Based on the transaction evidence, acquirers in the proteomics space consistently prioritize six characteristics: clinical-grade quality systems and regulatory optionality; high-multiplex capabilities; biofluids compatibility (blood-based assays are more commercially scalable than tissue-based ones); pharma validation; data assets (proprietary datasets that improve assay performance or provide clinical reference ranges); and integration compatibility.

Companies that can demonstrate strength across three or more of these dimensions are positioned for premium outcomes.

The Private Company Opportunity

The proteomics market has a large and largely unconsolidated middle layer of specialized private companies: niche antibody producers, specialty reagent manufacturers, proteomics CROs, bioinformatics tool developers, and application-specific assay companies. Many of these businesses operate at healthy margins with strong customer loyalty and recurring revenue, but have not engaged with the M&A market.

For founders and owners in this space, the window for premium strategic exits is open now. The large-cap acquirers are actively building out their proteomics portfolios. The PE roll-up interest is real and growing. And the valuation benchmarks set by Olink and Abcam create a reference frame that supports premium pricing for well-positioned private assets.

Conclusion

Proteomics is not a niche academic discipline. It is the analytical foundation for the next generation of drug discovery, biomarker development, and clinical diagnostics. The $28-36 billion market is expanding at 12-15% annually, driven by forces that are structural rather than cyclical: the shift to precision medicine, the maturation of mass spectrometry and affinity-based platforms, and the integration of AI into protein biology.

For investors and business owners, the proteomics market combines the financial characteristics of the best software businesses (high gross margins, recurring revenue, switching costs) with the strategic importance of critical infrastructure. The largest companies in life sciences are paying multi-billion dollar premiums to acquire proteomics capabilities. The private market opportunity, in the fragmented layer of specialized operators below the large caps, remains significant and underexplored by most advisors.

MaTrx advises life sciences companies, including proteomics tools, reagent, and services businesses, on sell-side M&A, capital raises, and strategic positioning. This report is the first in our Omics Series.

MaTrx is an AI-native investment bank and advisory firm serving the lower middle market. We advise life sciences, reagent, proteomics, and clinical laboratory businesses on M&A, capital raising, and restructuring.